Total
0
Shares
HeraMED (ASX:HMD) - CEO, David Groberman
CEO, David Groberman
Source: TechInvest Magazine
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Pregnancy technology company HeraMED (HMD) has signed a commercial agreement with Joondalup Health Campus (JHC)
  • Under the agreement, JHC will conduct a paid pilot of the company’s HeraCARE solution, involving 100 expectant mothers
  • Once the pilot is completed, HeraMED and JHC plan to enter into a comprehensive collaboration agreement
  • Under that agreement, the companies will deploy the HeraCARE platform as a standard service for all pregnant mothers at JHC
  • HeraMED is up four per cent and trading at 13 cents per share

Pregnancy technology company HeraMED (HMD) has signed a commercial agreement with Joondalup Health Campus (JHC).

Under the agreement, JHC will conduct a paid pilot of HeraMED’s HeraCARE solution, involving 100 expectant mothers. The pilot will allow these women to test the company’s comprehensive digital maternity care platform, which includes the HeraBEAT device.

The HeraBEAT device is a foetal and maternal heart rate monitor that can be used at home by the mother, allowing it to be used during remote telehealth consultations. JHC previously conducted a clinical trial of the HeraBEAT device, which produced excellent results in accuracy last year.

The device was able to detect the foetal heart rate 100 per cent of the time when used by clinicians and was also able to detect it 100 per cent of the time when used by expectant mothers without professional assistance.

HeraMED’s CEO, David Groberman, expressed the company’s delight at reaching this agreement with JHC.

“Representing the first agreement for the full-blown HeraCARE platform, on a Technology as a Service basis, it is in line with our commercialisation strategy and is expected to underpin further awareness of our technology amongst global healthcare providers,” he said.

“It is particularly pleasing that JHC have adopted HeraMED’s innovative technology, as it forms part of their strategic plan to become market leaders in adopting innovative care models based on digital health, home-based remote monitoring,” he added.

JHC will pay each user of the HeraCARE platform $50 a month during the pilot process. Once the pilot is completed, HeraMED and JHC intend to enter into a comprehensive follow-up collaboration agreement.

Under the follow-up agreement, the companies intend to fully deploy the HeraCARE platform as a standard service, available to all expectant mothers under JHC’s care. 

HeraMED is up four per cent, trading at 13 cents per share at 10:16 am AEST.

HMD by the numbers
More From The Market Herald
Amplia Therapeutics - CEO and MD, John Lambert

" Amplia Therapeutics (ASX:ATX) granted $2.1 million R&D cash flow loan

Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan.
Creso Pharma (ASX:CPH) - Creso Pharma

" Creso Pharma’s (ASX:CPH) Halucenex secures Dealer’s Licence amendment

Halucenex Life Sciences, a subsidiary of Creso Pharma (CPH), has secured an amendment to its Controlled Drugs and Substances Dealer’s Licence.

" Immutep (IMM) treats first five patients in solid tumour study

Immutep (IMM) has treated five patients in its study evaluating eftilagimod (efti) alpha in conjunction with standard of care chemotherapy.
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) granted ethics approval for chronic pain trial

Zelira Therapeutics (ZLD) has received ethics approval for its Phase 2a clinical trial for chronic pain.